| Hugh Ralph Holmquist, MD | |
|
410 South 8th Ave, Burwell, NE 68823 | |
| (308) 346-5544 | |
| (308) 346-4744 |
| Full Name | Hugh Ralph Holmquist |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 31 Years |
| Location | 410 South 8th Ave, Burwell, Nebraska |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1386648012 | NPI | - | NPPES |
| 47083890800 | Medicaid | NE | |
| 35194 | Other | NE | BLUE CROSS BLUE SHIELD |
| 47083890826 | Medicaid | NE | |
| 47083890820 | Medicaid | NE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 19518 (Nebraska) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Aseracare Hospice | Norfolk, NE | Hospice |
| Vchs Hospice | Ord, NE | Hospice |
| Valley County Health System | Ord, NE | Hospital |
| The Nebraska Medical Center | Omaha, NE | Hospital |
| Chi Health St. Francis | Grand island, NE | Hospital |
| Community Memorial Health Center | Burwell, NE | Nursing home |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Burwell Family Practice Pc | 7719081827 | 2 |
News Archive
EpiCept Corporation today announced that the National Cancer Institute (NCI) has initiated a Phase II trial with crolibulinTM (EPC2407). The trial will assess the drug's efficacy and safety in combination with cisplatin in patients with anaplastic thyroid cancer (ATC). CrolibulinTM is a vascular disruption and apoptosis inducing agent that has demonstrated potent anti-tumor activity in both preclinical and early clinical studies.
As we grow older, we lose strength and muscle mass. However, the cause of age-related muscle weakness and atrophy has remained a mystery.
Treatment to reduce recurrence of hepatitis B appears to improve liver transplant outcomes for some patients, according to a Mayo Clinic study presented at the American Transplant Congress under way May 1-5 in San Diego.
Sleep deprivation may result in people consuming more calories during the following day, according to a systematic review and meta-analysis led by researchers at King's College London.
› Verified 9 days ago
| Entity Name | Burwell Family Practice Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1932124732 PECOS PAC ID: 7719081827 Enrollment ID: O20080508000406 |
News Archive
EpiCept Corporation today announced that the National Cancer Institute (NCI) has initiated a Phase II trial with crolibulinTM (EPC2407). The trial will assess the drug's efficacy and safety in combination with cisplatin in patients with anaplastic thyroid cancer (ATC). CrolibulinTM is a vascular disruption and apoptosis inducing agent that has demonstrated potent anti-tumor activity in both preclinical and early clinical studies.
As we grow older, we lose strength and muscle mass. However, the cause of age-related muscle weakness and atrophy has remained a mystery.
Treatment to reduce recurrence of hepatitis B appears to improve liver transplant outcomes for some patients, according to a Mayo Clinic study presented at the American Transplant Congress under way May 1-5 in San Diego.
Sleep deprivation may result in people consuming more calories during the following day, according to a systematic review and meta-analysis led by researchers at King's College London.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Hugh Ralph Holmquist, MD Po Box 906, Burwell, NE 68823-0906 Ph: (308) 346-5544 | Hugh Ralph Holmquist, MD 410 South 8th Ave, Burwell, NE 68823 Ph: (308) 346-5544 |
News Archive
EpiCept Corporation today announced that the National Cancer Institute (NCI) has initiated a Phase II trial with crolibulinTM (EPC2407). The trial will assess the drug's efficacy and safety in combination with cisplatin in patients with anaplastic thyroid cancer (ATC). CrolibulinTM is a vascular disruption and apoptosis inducing agent that has demonstrated potent anti-tumor activity in both preclinical and early clinical studies.
As we grow older, we lose strength and muscle mass. However, the cause of age-related muscle weakness and atrophy has remained a mystery.
Treatment to reduce recurrence of hepatitis B appears to improve liver transplant outcomes for some patients, according to a Mayo Clinic study presented at the American Transplant Congress under way May 1-5 in San Diego.
Sleep deprivation may result in people consuming more calories during the following day, according to a systematic review and meta-analysis led by researchers at King's College London.
› Verified 9 days ago